• Publications
  • Influence
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
Acquired immune deficiency syndrome (AIDS) is characterized by opportunistic infections and by ‘opportunistic neoplasms’ (for example, Kaposi's sarcoma)1. Persistent generalized lymphadenopathy (PGL)Expand
  • 1,888
  • 87
Kaposi's sarcoma.
Kaposi's Sarcoma (KS) remains an enigma over 100 years after it was first described by a Hungarian dermatologist who ensured his place in the hall of fame by changing his name to the exotic 'Kaposi',Expand
  • 519
  • 51
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain
The isolation of clones encoding the human surface protein T4, and the expression of the T4 gene in new cellular environments, have enabled us to examine the role of this protein in the pathogenesisExpand
  • 957
  • 33
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Thalidomide was originally used to treat morning sickness, but was banned in the 1960s for causing serious congenital birth defects. Remarkably, thalidomide was subsequently discovered to haveExpand
  • 624
  • 21
A new disease has recently been recognised in rural Uganda. Because the major symptoms are weight loss and diarrhoea, it is known locally as slim disease. It is strongly associated with HTLV-IIIExpand
  • 394
  • 21
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Lenalidomide (Revlimid®; CC-5013) and pomalidomide (CC-4047) are IMiDs® proprietary drugs having immunomodulatory properties that have both shown activity in cancer clinical trials; lenalidomide isExpand
  • 292
  • 15
In vivo cellular tropism of human T-cell leukemia virus type 1.
To establish the phenotype of human T-cell leukemia virus type 1 (HTLV-1)-infected cells in peripheral blood, the polymerase chain reaction was used to detect and quantitate viral DNA inExpand
  • 310
  • 12
Proteinase Inhibitors
  • 194
  • 11
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
PURPOSE To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma. PATIENTS AND METHODS Twenty-fourExpand
  • 288
  • 8
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
Background:Some cancer patients are immuno-compromised, and it has been long felt that immune-intervention is not compatible with standard chemotherapies. However, increasing evidence suggests thatExpand
  • 177
  • 8